With an eye on treatment
we are dedicated to addressing patient needs with lasting impact.
YUTIQ is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.
Alimera Sciences, Inc. has rights for non-infectious posterior uveitis in the EMEA.
Rights for China, Hong Kong, Taiwan, Macau, Korea, and certain SE Asia countries licensed to Ocumension with a royalty on sales payable to EyePoint.
30,000 patients in the US become blind each year because of posterior uveitis
We developed a solution
Posterior uveitis lasts a lifetime and often affects people in the prime of their working lives.